CClinicalTrials.gg
Status unknownNCT04637061REC4TUpdated Nov 25, 2020

Rectal Cancer Anastomosis 4 Check Study

An observational study in Rectal Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-25.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
287
Ages
18 Years and older
Sex
All
01

Study summary

Anastomotic failure (AF), including anastomotic leakage (AL), increases morbidity and mortality after colorectal cancer (CRC) resection. An inadequate perfusion of the anastomosis or technical stapling defects may contribute to AF. Several studies evaluated the singular use of intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis. So far, a combined use of these methodologies, although acknowledged has not yet been tested as an indicator of postoperative AF or of intra-operative anastomotic repair in a prospective setting. This study aims to implement the intraoperative anastomotic assessment in a prospective series of patients undergoing rectal resection plus primary anastomosis for rectal cancer with or without ostomy, using a semi-quantitative check of 4 items (4-check). The procedure will include NIR-ICG-induced FA (to assess perfusion), air leak test and evaluation of the anastomotic donuts (to assess for the presence of technical defects). Included patients will be those scheduled for elective rectal resection with total or partial mesorectal excision and primary colo-rectal anastomosis with/or without protective ostomy. Primary outcomes will be the overall incidence of intra-operative anastomotic repair and the rate of post-operative AF. Secondary outcomes will be the overall incidence of adverse events and serious complications, the estimation of costs and resources, the operative time, hospitalization and post-operative measurement of inflammatory markers.

Read the detailed description

All consecutive patients undergoing rectal resection (open and mini-invasive procedures) plus primary anastomosis for rectal cancer selected for the study will udergo a surgical intra-operative assessment of the anastomosis based on the check of the following 4 items (4-check):

  1. Extra-luminal (serosa) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative assessment of the near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA).
  2. Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative assessment of the NIR-ICG-induced FA.
  3. Air leak test (extra-luminal and reverse).
  4. Assessment of the anastomotic donuts. aiming to test the efficacy of the procedure (overall incidence of intra-operative anastomosis repairs) and the overall incidence of anastomotic failure
02

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • rectal cancer
  • indocyanine green
  • fluorescence angiography
  • surgery
03

In context

Rectal Neoplasms

1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's planned enrollment of 287 is above the median of 160 across 413 observational studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 920 studies on the registry; 529 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Selected patients will receive oral bowel preparation as for colonoscopy, 2 days before surgery and managed with ERAS protocol. Patients should be treated with rectal resection with TME or PME and mechanical anastomosis with a circular stapler, using one of the following approaches:

  1. Open surgery.
  2. Laparoscopic surgery (operations performed through small incisions and ports placements independently from the type and length of incision for specimen extraction).
  3. Robot-assisted surgery (using robotic systems to aid in surgical procedures independently from the type and length of incision for specimen extraction).
  4. TaTME. Mini-invasive bottom up approach for mesorectal dissection and colorectal anastomosis using a single/double team, independently from the type and length of incision for specimen extraction.

The following procedures is required during surgery:

Routine splenic flexure mobilization.

Inclusion criteria

  • 18 years or older.
  • Rectal adenocarcinoma or benign polyp with indication for rectal resection with total or partial mesorectal excision and primary colo-rectal anastomosis with/or without protective ostomy.
  • Patients undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery.
  • Patients with adequate performance status (Eastern Cooperative Oncology Group Scale score of ≤2).
  • Patient must sign the Informed Consent Form (ICF) before any study procedures and agrees to attend all study visits.
  • Selection of the patient before inclusion.

Exclusion criteria

Exclusion Criteria:

    • Patient pregnant or suspected pregnancy.

      • Patient with a comorbid illness or condition that would preclude the use of surgery.
      • Past medical history of Inflammatory Bowel Disease (IBD).
      • Synchronous cancers requiring extended sub-total or total colectomies.
      • Long lasting therapy with steroids to be continued in the peri-operative period (4 weeks previous and 4 weeks after surgery).
      • Use of antiplatelet drug (anti-aggregant) and/or oral anti-coagulant drug to be continued in the peri-operative period (1 week previous and 4 weeks after surgery).
      • Patients assessed as American Society of Anesthesiologists (ASA) physical status 4.
      • Patients with clinical stage of cT4b tumor after neoadjuvant theapy.
      • Metastatic disease (clinical Stage 4).
      • Patient undergoing emergency procedures.
      • Planned colonic surgery along with major concomitant procedures (i.e. liver resections, other intestinal resections).
      • Previous colon surgery (excluding appendectomy).
      • Non-restorative procedures (i.e. Miles or Hartman resection).
      • Colo-anal manual anastomosis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
287 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • REC4T study patients

    Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)

    Combination Product: intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis · Diagnostic Test: Air Leak test · Diagnostic Test: Evaluation of the anastomotic rings

Interventions

  • Combination productintraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis

    Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.

    Also known as: Near Infrared Fluorescence angiography, indocyanine green

  • Diagnostic testAir Leak test

    This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.

  • Diagnostic testEvaluation of the anastomotic rings

    The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete

06

What researchers measure

Primary outcomes

  1. intra-operative anastomosis repairs

    defined as additional suturing or re-do anastomosis

    Time frame: 01/01/2021 to 31/12/2022

  2. Rate of 30 day-anastomotic failure (AF)

    defined as anastomotic-related morbidity, including anastomotic leakage, pelvic abscess, anastomotic-related fistula, sinus, and anastomotic stricture

    Time frame: 01/01/2021 to 31/12/2022

Secondary outcomes

  1. Rate of of adverse events

    any medical or surgical complications

    Time frame: 01/01/2021 to 31/12/2022

  2. Rate of 30-day major complications

    Clavien-Dindo grade IIIb-IV

    Time frame: 01/01/2021 to 31/12/2022

  3. Measure of costs

    Costs resource utilization for the procedure

    Time frame: 01/01/2021 to 31/12/2022

  4. Medan length of post-operative stay

    post-operative stay (measured in days)

    Time frame: 01/01/2021 to 31/12/2022

  5. C-Reactive Protein (CRP) measurement

    measurement conducted in postoperative days 1, 3 \& 5 (optional) using mg/L

    Time frame: 01/01/2021 to 31/12/2022

  6. Procalcitonin (PCT) measurement

    measurement conducted in postoperative days 1, 3 \& 5 (optional) using mg/L ng/mL

    Time frame: 01/01/2021 to 31/12/2022

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04637061
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Responsible party
Sponsor
First posted
Nov 19, 2020
Start date
Jan 1, 2021 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Nov 25, 2020

Study contacts

Roberto Persiani, MD
Contact
roberto.persiani@policlinicogemelli.it
0630154511 ext. 0630154511
Laura Lorenzon, MD PhD
Contact
laura.lorenzon@policlinicogemelli.it
Roberto Persiani, MD
principal investigator · Fondazione Policlinico Universitarioa A Gemelli IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion